Font Size




Menu Style

AVG Home


AVG Webinar Series

Webinar 2 on Antiviral Resistance took place on Tuesday 24 January and you can listen to the recording via this link.

There were 4 talks covering SARS-CoV-2, flu and RSV.

The coronavirus helicase contributes to remdesivir resistance but impairs virus fitness and helicase function – Professor Mark Denison, Vanderbilt University Medical Center, Nashville, TN, USA

SARS-CoV-2 resistance to antibodies and protease inhibitors - Dr Emi Takashita, National Institute of Infectious Diseases, Tokyo, Japan

Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission - Dr Jeremy Jones, St. Jude Children’s Research Hospital, Memphis TN, USA

Monoclonal antibodies and promising antivirals for RSV – the challenges  - Professor Tony Piedra, Baylor College of Medicine, Houston, TX, USA

Dates for next webinars:

25 April – ‘The Present and Future of Treatment Oriented Surveillance’

Webinar Chair: Dr Angie Lackenby, Clinical Scientist, UK Health Security Agency, London, UK

Talk 1 - Dr Theo Sanderson, Sir Henry Wellcome Fellow at The Francis Crick Institute, London, UK

‘Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases’

Watch this space for details on the other short talks!

20 June (NOTE REVISED DATE) – Clinical Trial Updates

Time: 8.30am ET/ 1.30pm UK/ 2.30pm CET/ 9.30pm CST

If you missed Webinar 1 you can listen to it via this link.


7th AVG Conference (in-person)

Visit the conference website here


Recent Virtual Conference

The ISIRV-WHO virtual conference, held last October, was attended by a global audience of over 730 attendees from 71 countries!  The recordings from this conference are now available here and the Conference Report can be found here.
SARS-CoV-2 / COVID-19   
Antiviral News

AVG Overview

The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More


   isirv Antiviral Group (isirv-AVG) 10th Anniversary

The isirv Antiviral Group was established in 2011 following the merger of the Neuraminidase Inhibitor Susceptibility Network (NISN) with the International Society for Influenza and Other Respiratory Virus Diseases (isirv). Read more

To fulfil its objectives of promoting understanding of the development and clinical use of antivirals against respiratory viruses and the emergence of resistance, the Group has organised a series of AVG conferences on specific topics in different geographical locations plus other smaller specialist meetings and workshops.

The Group gratefully acknowledges the contribution of its partners and the generous financial support from many privateand public organisations that have ensured the success of the Group’s programme of events over the past 10 years.

 Recent AVG Events

Therapeutics for COVID-19, a special virtual conference, 6-8 October 2020
The 3-day programme addressed the latest advances in the development of antivirals and other therapeutics for use against COVID-19 and possibilities for improved clinical management. Oral and e-poster presentations are available. Read more
AVG Polymerase Inhibitor Resistance Meeting, at the Offices of the Task Force for Global Health, Atlanta, USA, 7-8 August 2019
The participants at this small specialist meeting, including public health, academic and corporate representatives who are conducting studies on the new antivirals targeting the influenza RNA polymerase, met to discuss the impact of resistance to these inhibitors. A report of the meeting is incorporated in an Assessment of the Current State of the Art report published in Antiviral Research and now on the AVR journal web site as a highlighted article. Read more
6th ISIRV-AVG Conference: Advances in Respiratory Virus Therapeutics, Washington DC, USA 13-15 November 2018
This conference addressed both pre-clinical and clinical advances in therapeutic and prophylactic agents for influenza, RSV and other respiratory viruses and regulatory issues central to advancing such agents to clinical practice. The report was published in Antiviral Research and can be viewed here.
Highlights from Influenza 2018: Centenary of the 1918 Pandemic, 24-26 June at The Crick, London
The greatest public health disaster in recorded history, the Spanish Flu, began in springtime of 1918 and developed within a few months into a global pandemic with an estimated 50-100 million deaths. By its end, the pandemic had caused a reduction of life expectancy in the US by 12 years, and killed more people than died in the First World War. Read more

Antiviral News


Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials...  read more

Influenza antivirals and their role in pandemic preparedness...  read more

An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance...  read more

Neuraminidase Inhibitors
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020... read more
Clinical Trials & Case Studies
Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial... read more
Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment... read more
Baloxavir Marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes
A single, oral dose of baloxavir marboxil was well-tolerated, and rapidly reduced viral titers, but the common emergence of PA/I38T/M-substituted viruses warrants consideration of alternative dosing regimens in young children…read more
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
The kinetics, risk factors, and effects on clinical and virologic outcomes of emergence of PA/I38X-substituted viruses was evaluated. The emergence of viruses with PA/I38X substitutions following baloxavir treatment was associated with transient rises in infectious virus titers, prolongation of virus detectability, initial delay in symptom alleviation, and uncommonly with symptom more
Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS).
A total of 2131 children infected with influenza (683 A/H1N1pdm09; 825 A/H3N2; 623 influenza B) were investigated. Children aged 1>5 years had a higher total viral burden with prolonged virus shedding and had an increased risk of acquiring resistance mutations following antiviral treatment…read more
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial 
This study shows that single-dose baloxavir has superior efficacy to placebo and similar efficacy to oseltamivir for ameliorating influenza symptoms in high-risk outpatients. The safety of baloxavir was comparable to placebo …read more
Visit us on:  facebook  twitter